A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia

Psychiatry Research

Volumn 215, Issue 2, 2014, Pages 268-273

  Niitsu, Tomihisa ^a   Ishima, Tamaki ^b   Yoshida, Taisuke ^a   Hashimoto, Tasuku ^a   Matsuzawa, Daisuke ^a   Shirayama, Yukihiko ^c   Nakazato, Michiko ^a   Shimizu, Eiji ^a   Hashimoto, Kenji ^b   Iyo, Masaomi ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

Biomarker; ELISA; Gender; Mature BDNF; MMP 9; SANS; Smoking

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; GELATINASE B;

ADULT; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; SCHIZOPHRENIA; SEX DIFFERENCE;

ADULT; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS;

EID: 84893780369     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.12.009     Document Type: Article

References (42)

1. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacological Reviews 2012, 64:238-258.
2. Carlino D., De Vanna M., Tongiorgi E. Is altered BDNF biosynthesis a general feature in patients with cognitive dysfunctions?. The Neuroscientist 2013, 19:345-353.
3. Carlino D., Leone E., Di Cola F., Baj G., Marin R., Dinelli G., Tongiorgi E., De Vanna M. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. Journal of Psychiatric Research 2011, 45:273-279.
4. Carter C.S., Mintun M., Cohen J.D. Interference and facilitation effects during selective attention: an H215O PET study of Stroop task performance. NeuroImage 1995, 2:264-272.
5. Chan M.W., Yip J.T., Lee T.M. Differential impairment on measures of attention in patients with paranoid and nonparanoid schizophrenia. Journal of Psychiatric Research 2004, 38:145-152.
6. Chen da C., Wang J., Wang B., Yang S.C., Zhang C.X., Zheng Y.L., Li Y.L., Wang N., Yang K.B., Xiu M.H., Kosten T.R., Zhang X.Y Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 2009, 207:375-380.
7. Domenici E., Wille D.R., Tozzi F., Prokopenko I., Miller S., McKeown A., Brittain C., Rujescu D., Giegling I., Turck C.W., Holsboer F., Bullmore E.T., Middleton L., Merlo-Pich E., Alexander R.C., Muglia P. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 2010, 5:e9166.
8. Ethell I.M., Ethell D.W. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. Journal of Neuroscience Research 2007, 85:2813-2823.
9. Favalli G., Li J., Belmonte-de-Abreu P., Wong A.H., Daskalakis Z.J. The role of BDNF in the pathophysiology and treatment of schizophrenia. Journal of Psychiatric Research 2012, 46:1-11.
10. Fernandes B.S., Massuda R., Torres M., Camargo D., Fries G.R., Gama C.S., Belmonte-de-Abreu P.S., Kapczinski F., Lobato M.I. Improvement of schizophrenia with electroconvulsive therapy and serum brain-derived neurotrophic factor levels: lack of association in a pilot study. Psychiatry and Clinical Neurosciences 2010, 64:663-665.
11. Goto N., Yoshimura R., Kakeda S., Moriya J., Hayashi K., Ikenouchi-Sugita A., Umene-Nakano W., Hori H., Ueda N., Korogi Y., Nakamura J. Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls. European Psychiatry 2011, 26:57-63.
12. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Molecular Psychiatry 2011, 16:960-972.
13. Hashimoto K. BDNF variant linked to anxiety-related behaviors. BioEssays 2007, 29:116-119.
14. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry and Clinical Neurosciences 2010, 64:341-357.
15. Hashimoto K. A BDNF Val66Met polymorphism and ketamine-induced rapid antidepressant action. Clinical Psychopharmacology and Neuroscience 2012, 10:59-60.
16. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Progress in Neurobiology 2013, 100:15-29.
17. Hori H., Noguchi H., Hashimoto R., Nakabayashi T., Omori M., Takahashi S., Tsukue R., Anami K., Hirabayashi N., Harada S., Saitoh O., Iwase M., Kajimoto O., Takeda M., Okabe S., Kunugi H. Antipsychotic medication and cognitive function in schizophrenia. Schizophrenia Research 2006, 86:138-146.
18. Huang T.L., Lee C.T. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. Journal of Psychiatric Research 2006, 40:664-668.
19. Hwang J.J., Park M.H., Choi S.Y., Koh J.Y. Activation of the Trk signaling pathway by extracellular zinc. Role of metalloproteinases. The Journal of Biological Chemistry 2005, 280:11995-12001.
20. Igarashi K., Oguni H., Osawa M., Awaya Y., Kato M., Mimura M., Kashima H. Wisconsin card sorting test in children with temporal lobe epilepsy. Brain and Development 2002, 24:174-178.
21. Lee A.H., Lange C., Ricken R., Hellweg R., Lang U.E. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. Journal of Clinical Psychopharmacology 2011, 31:334-336.
22. Lu B. Pro-region of neurotrophins: role in synaptic modulation. Neuron 2003, 39:735-738.
23. Lu B., Pang P.T., Woo N.H. The yin and yang of neurotrophin action. Nature Reviews Neuroscience 2005, 6:603-614.
24. Mackin P., Gallagher P., Watson S., Young A.H., Ferrier I.N. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. The Australian and New Zealand Journal of Psychiatry 2007, 41:321-326.
25. Martinotti G., Di Iorio G., Marini S., Ricci V., De Berardis D., Di Giannantonio M. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. Journal of Biological Regulators and Homeostatic Agents 2012, 26:347-356.
26. 2+ in rodent microglia. Journal of Immunology 2009, 183:7778-7786.
27. Niitsu T., Shirayama Y., Matsuzawa D., Hasegawa T., Kanahara N., Hashimoto T., Shiraishi T., Shiina A., Fukami G., Fujisaki M., Watanabe H., Nakazato M., Asano M., Kimura S., Hashimoto K., Iyo M. Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2011, 35:1836-1840.
28. Nurjono M., Lee J., Chong S.A. A review of brain-derived neurotrophic factor as a candidate biomarker in schizophrenia. Clinical Psychopharmacology and Neuroscience 2012, 10:61-70.
29. Pillai A., Kale A., Joshi S., Naphade N., Raju M.S., Nasrallah H., Mahadik S.P. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. The International Journal of Neuropsychopharmacology 2010, 13:535-539.
30. Reis H.J., Nicolato R., Barbosa I.G., Teixeira do Prado P.H., Romano-Silva M.A., Teixeira A.L. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neuroscience Letters 2008, 439:157-159.
31. Rizos E.N., Michalopoulou P.G., Siafakas N., Stefanis N., Douzenis A., Rontos I., Laskos E., Kastania A., Zoumpourlis V., Lykouras L. Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia. Neuropsychobiology 2010, 62:87-90.
32. Rizos E.N., Papadopoulou A., Laskos E., Michalopoulou P.G., Kastania A., Vasilopoulos D., Katsafouros K., Lykouras L. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. The World Journal of Biological Psychiatry 2010, 11:251-255.
33. Rizos E.N., Papathanasiou M., Michalopoulou P.G., Mazioti A., Douzenis A., Kastania A., Nikolaidou P., Laskos E., Vasilopoulou K., Lykouras L. Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naive schizophrenic patients. Schizophrenia Research 2011, 129:201-204.
34. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., Shinoda N., Nakazato M., Kumakiri C., Okada S., Iyo M. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neuroscience Letters 2003, 351:111-114.
35. Sumiyoshi C., Sumiyoshi T., Nohara S., Yamashita I., Matsui M., Kurachi M., Niwa S. Disorganization of semantic memory underlies alogia in schizophrenia: an analysis of verbal fluency performance in Japanese subjects. Schizophrenia Research 2005, 74:91-100.
36. Yang Y.Q., Sun S., Yu Y.Q., Li W.J., Zhang X., Xiu M.H., Chen da C., De Yang F., Liu H., Li C., Kosten T.R., Zhang X.Y. Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia. Neuroscience Letters 2011, 502:37-40.
37. Yoshida T., Ishikawa M., Iyo M., Hashimoto K. Serum levels of mature Brain-Derived Neurotrophic Factor (BDNF) and its precursor proBDNF in healthy subjets. The Open Clinical Chemistry Journal 2012, 5:7-12.
38. Yoshida T., Ishikawa M., Niitsu T., Nakazato M., Watanabe H., Shiraishi T., Shiina A., Hashimoto T., Kanahara N., Hasegawa T., Enohara M., Kimura A., Iyo M., Hashimoto K. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS ONE 2012, 7:e42676.
39. Zhang X.Y., Chen da C., Xiu M.H., Haile C.N., Luo X., Xu K., Zhang H.P., Zuo L., Zhang Z., Zhang X., Kosten T.A., Kosten T.R. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Human Genetics 2012, 131:1187-1195.
40. Zhang X.Y., Liang J., Chen da C., Xiu M.H., Yang F.D., Kosten T.A., Kosten T.R. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology (Berl) 2012, 222:277-284.
41. Zhang X.Y., Xiu M.H., Chen da C., Yang F.D., Wu G.Y., Lu L., Kosten T.A., Kosten T.R. Nicotine dependence and serum BDNF levels in male patients with schizophrenia. Psychopharmacology (Berl) 2010, 212:301-307.
42. Zhang X.Y., Zhang W.F., Zhou D.F., Chen da C., Xiu M.H., Wu H.R., Haile C.N., Kosten T.A., Kosten T.R. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biological Psychiatry 2012, 72:700-706.